- Trustees, Management & Advisers
Trustees, Management & Advisers
Trustees
- Professor Paul Lorigan (chairman; professor of medical oncology, University of Manchester)
- Dr Katharine Acland (consultant dermatologist, Guy’s & St Thomas’ NHS Trust)
- Mrs Deborah Beirne (nurse consultant clinical research, Leeds Teaching Hospitals NHS Trust)
- Professor Martin Cook (consultant histopathologist, Royal Surrey County Hospital)
- Dr Pippa Corrie (consultant medical oncologist, Cambridge University Hospitals NHS Foundation Trust)
- Dr Mark Harries (consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust)
- Professor Richard Marais (scientist, CRUK Manchester Institute)
- Dr Jerry Marsden (consultant dermatologist, Queen Elizabeth Hospital Birmingham)
- Dr Paul Nathan (consultant medical oncologist, Mount Vernon Cancer Centre)
- Mr Howard Peach (consultant plastic and reconstructive surgeon, Leeds Teaching Hospitals NHS Trust)
- Professor Barry Powell (consultant plastic and reconstructive surgeon, St George’s Healthcare NHS Trust)
Management and Advisers
- Chief Executive Officer: Simon Rodwell
- Financial Adviser: Stephen Sandys
NHS changes stopping/retreatment funding rules for immunotherapy patients
NHS England is revising its ruling that has blocked funds for the re-starting of anti PD-1 treatments for patients with melanoma. Clinicians will be able to halt treatment after two years knowing that funding for the drugs will be available if the disease progresses and the treatment needs to be resumed in the future.
READ MOREFlu vaccination: melanoma immunotherapy patients advised they should still receive jab
Immunology expert Professor Christian Ottensmeier says he believes that for these patients there is more harm in NOT vaccinating against flu than there is in vaccinating against it: ‘For inactivated vaccines such as the flu, I tell my patients to continue to have this form of protection.’
READ MOREFirst safe and effective adjuvant therapy for melanoma is now available on the NHS
Patients and clinicians have welcomed the announcement of a new adjuvant therapy drug combination. ‘This is the first treatment to be made available that shows a significant reduction in the risk of dying from the recurrence of melanoma after surgery,’ says Melanoma Focus Chairman Professor Paul Lorigan. ‘This milestone will transform outcomes for many patients’.
READ MORE
100 Miles in May Challenge Event
100 Miles in May is a challenge event that anyone can take part in whether they are a cyclist, runner, walker or swimmer. Join the challenge and help raise money in the fight against melanoma.
READ MORE